Mission Bay Capital backs Circle Pharma

San Francisco-based early-stage biotech firm Circle Pharma said Monday that it has secured an undisclosed amount of seed funding. The investors were Pfizer and QB3’s seed-stage venture fund Mission Bay Capital.


Dutch biotech firm ProQR Therapeutics debuts IPO

ProQR Therapeutics said Thursday that it has priced its IPO of 7.5 million shares at $13 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “PRQR.” Leerink Partners and Deutsche Bank Securities are serving as lead underwriters. Based in the Netherlands, ProQR Therapeutics is a biopharmaceutical firm focused on treating severe genetic disorders.

Rapper Nas 2014 by Reuters

Top 10 posts: venture capital

Venture capital-related stories trending on peHUB this week: Investors wide awake for Wakie, rapper Nas joins Accel Partners and the Manning brothers in a $35 million round for SeatGeek, and biotech IPO fever continues.

FortuneRock (China) snags $24 mln

FortuneRock (China) has raised $24 million in funding. The investors included Jinhua Pharmaceutical Co. Ltd. Based in Beijing, FortuneRock (China) is a biotech and biopharmaceutical firm.


Accelerator Corp raises $51.1 mln for fourth fund

Accelerator Corp. said Tuesday that it has raised $51.1 million in the first close of its fourth fund. The pool’s investors include Alexandria Venture Investments, ARCH Venture Partners, WRF Capital, Eli Lilly, Harris & Harris Group, Johnson & Johnson Development Corp., The Partnership Fund for New York City and Pfizer Venture Investments. Based in Seattle and New York City, Accelerator Corp is a biotech investment firm.


Atlas Ventures and NEA back Synlogic

Synlogic said Tuesday that it has received $29.4 million in Series A funding. Atlas Venture and New Enterprise Associates led the round. In conjunction with the funding, Dr. Peter Barrett and Dr. Ankit Mahadevia of Atlas Venture and Ed Mathers of NEA have been appointed to Synlogic’s board of directors. Based in Cambridge, Mass., Synlogic is a biotech firm focused on developing therapeutic microbes.

DesignMedix grabs $1.5 mln

Portland, Oregon-based biotech startup DesignMedix has raised $1.5 million in funding. The investors included Portland Seed Fund.


Emerald Therapeutics snags Series B funds

Emerald Therapeutics, a biotech firm based in Menlo Park, Calif., has closed its latest Series B funding round, raising the total financing to $13.5 million. Founders Fund and PayPal co-founder Max Levchin were the lead investors. Schooner Capital also participated in the round.

Atlas Venture and Lilly Ventures leads $8 mln round for Numerate

Biotech firm Numerate has closed $8 million in financing. Atlas Venture and Lilly Ventures led the round. In addition to the financing, Dr. Bruce Booth, a partner at Atlas Venture and Dr. Steve Hall, a venture partner at Lilly Ventures, have been added to Numerate’s board of directors.

Tyrogenex grabs $15 mln Series D

Tyrogenex, a biotech firm based in West Palm Beach, Florida, has closed $15 million in Series D financing. The backer was Brace Pharma, the U.S. investment arm of Brazilian pharmaceutical firm EMS. In conjunction with the funding, Vinzenz Ploerer, president and CEO of Brace Pharma, has been added to the Tyrogenex board of directors.

True North Therapeutics bags $22 mln Series A

South San Francisco-based biotech firm True North Therapeutics has closed $22 million in Series A funding. The investors included Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Biogen Idec New Ventures and Baxter Ventures.

VC-backed Solstice Biologics hires new president/CEO and CFO

San Diego-based biotech startup Solstice Biologics, which is backed by venBio and Aeris Capital, has hired Dr. Lou Tartaglia as president and CEO. Tartaglia has also been added to the firm’s board of directors. Also, the firm has named John Borgeson as chief financial officer. Previously, Tartaglia worked at Third Rock Ventures where he was a partner while Borgeson was vice president of finance for Pfizer‘s biotherapeutic and bioinnovation center.


Ignyta taps TPG Capital’s Chacko as CFO

Ignyta has hired Dr. Jacob Chacko as chief financial officer. He replaces Zachary Hornby, who has become the firm’s chief operating officer. Previously, Chacko worked at TPG Capital where he served as a vice president focused mostly on healthcare and digital media. Based in San Diego, Calif., Ignyta is a biotech firm that is developing precision medicine focused on treating cancer patients.


Rodin Therapeutics snags $12.9 mln Series A

Rodin Therapeutics has secured $12.9 million in Series A financing. Previous backers Atlas Venture and Johnson & Johnson Development Corp. led the round. Also, the company has named Barbara Tate as head of biology. Based in Cambridge, Mass., Rodin is a biotech firm focused on treating neurological disorders.

Week’s Top 10 Hub Posts Feature Powerful Women in PE, Zynga’s IPO and Big Biotech Deals

Here are this week’s top 10 posts based on number of pageviews from peHUB’s regular readers. Hot topics included powerful women in private equity, details of Zynga’s upcoming IPO and the biggest biotech deals of Q4 so far.

1. Slideshow: Five Powerful Women In Private Equityby Bernard Vaughan
2. Zynga’s IPO By The Numbers And A Look At Its Three Classes Of Stock: Slideshowby Mark Boslet
3. Slideshow: Where the Biotech & Device Investors Are–Q4 Editionby Jonathan Marino
4. Founders Fund on Monday Meetings, Patience, and That New $625 Million Fundby Connie Loizos
5. Wanted: Private Equity High-Flyers in Growth Areasby Reuters
6. Slideshow: A Selection of Euro Buyout Fund Terms and Conditionsby Angela Sormani
7. Eight Steps To Mastering Small Company Acquisitionsby Ben Smith
8. The Uniforms of Silicon Valley, a Slideshow (subscribers only) – by Connie Loizos
9. Quien Es Mas Macho? A Slideshow of the Top 5 U.S. PE Funds this Year (subscribers only) – by Luisa Beltran
10. Moody’s: Most Bubble-era LBOs Struggle, while Dollar General, HCA Shineby Luisa Beltran

Slideshow: Top 10 Sectors Backed by VCs in Q2; the Internet Isn’t the Only Game in Town

We reported last week that Internet investing helped drive second-quarter venture deal volume, but biotech, medical devices and software startups were strong money magnets as well. So were companies in IT services and entertainment, according to data from the MoneyTree Report, which is produced by PricewaterhouseCoopers and the National Venture Capital Association, based on data […]

PEHUB Community

Join the 12506 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget